Deno Gen (Beijing) Biotech Co., Ltd. is a Chinese national high-tech enterprise in R&D, production and sales of diagnostic reagents and automated testing equipment. The company’s base has two technical platforms for reagents and equipment, including dual-innovation R&D center models for automated equipment and diagnostic reagents in United States and China as preliminary research and development, and domestic pilot production and industrial production. Reagent matching instruments or instrument integration is the company’s core competitiveness.
Deno Gen is the world’s second core technology company with independent intellectual property rights to develop and manufacture gold standard (sanger) sequencing and capillary electrophoresis (CE) equipment (U1 gene analyzer). Facing COVID-19 crisis, Deno Gen responded quickly, developed and produced a new coronavirus (SARS-COV-2) nucleic acid detection kit (reverse transcription PCR fluorescent probe method). Deno Gen also launched the immune reagent product line and launched the “New Coronavirus IgG / IgM antibody rapid detection kit (colloidal gold method)” to cooperate with nucleic acid detection.
At present, COVID-19 Pandemic is spreading all over the world, and Deno Gen is producing with full power. At the same time, it has obtained EU CE related qualifications and will play a role in the global fight against the Pandemic. In addition to its self-produced capacity, Deno Gen will also fully utilize its various resource relationships in China, and has the ability to integrate materials including detection reagent, equipment and PPE related products.
For more details, please c check their website.
Please contact us at firstname.lastname@example.org if any assistance needed.